Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis
2023年10月至2024年3月,在美国婴儿首次呼吸道合胞病毒(RSV)感染季期间,nirsevimab 的有效性:一项基于检测阴性设计的分析
期刊:Lancet Regional Health-Americas
影响因子:7.6
doi:10.1016/j.lana.2025.101196
Payne, Amanda B; Battan-Wraith, Steph; Rowley, Elizabeth A K; Stockwell, Melissa S; Tartof, Sara Y; Dascomb, Kristin; Irving, Stephanie A; Dixon, Brian; Ball, Sarah W; Tenforde, Mark W; Vazquez-Benitez, Gabriela; Stephens, Ashley B; Han, Jungmi; Natarajan, Karthik; Salas, S Bianca; Bezi, Cassandra; Sy, Lina S; Lewin, Bruno; Sheffield, Tamara; Arndorfer, Julie; Bride, Daniel; Van Otterloo, Josh; Naleway, Allison L; Koppolu, Padma D; Grannis, Shaun; Fadel, William; Rogerson, Colin; Duszynski, Tom; Reese, Sarah E; Mitchell, Patrick K; Chickery, Sean; Moline, Heidi L; Najdowski, Morgan; Ciesla, Allison Avrich; Reeves, Emily L; DeSilva, Malini; Fleming-Dutra, Katherine E; Link-Gelles, Ruth